Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs BIO-TECHNE Corp — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 30× JPMorgan Diversified Return International Eqty ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and BIO-TECHNE Corp for 63 Days on average.
| JPIN | TECH | |
|---|---|---|
Market Cap | $378.77M | $11.36B |
Volume | 13,861 | 5,390,331 |
52-Week High | $77.80 | $72.61 |
52-Week Low | $64.96 | $43.31 |
Typical Hold Time | 120 Days | 63 Days |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.01, showing minimal daily movement with a 0.1% gain. Technical indicators are predominantly bearish, with moving averages and oscillators signaling selling pressure, though RSI levels suggest potential oversold conditions. The ETF, designed for international equity exposure, lacks current fundamental data for valuation ratios and profitability metrics.
The outlook remains cautious due to strong bearish technical signals and absence of recent financial updates. Key risks include market volatility and reliance on international equities. Investors should await earnings reports for fundamental clarity, as current data is insufficient to assess valuation or growth prospects.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
